Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium

被引:5
|
作者
Gerlier, Laetitia [1 ]
Lamotte, Mark [1 ]
Mendes, Sofia Dos Santos [2 ]
Damm, Oliver [3 ]
Schwehm, Markus [4 ]
Eichner, Martin [5 ,6 ]
机构
[1] IMS Hlth Real World Evidence Solut, Davos Bldg,Vincilaan 7, B-1935 Zaventem, Belgium
[2] SA AstraZeneca NV, Uccle, Belgium
[3] Univ Bielefeld, Bielefeld, Germany
[4] ExploSYS GmbH, Leinfelden Echterdingen, Germany
[5] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany
[6] Epimos GmbH, Dusslingen, Germany
关键词
COST-EFFECTIVENESS; YOUNG-CHILDREN; ECONOMIC BURDEN; UNITED-STATES; EFFICACY; ENGLAND; GERMANY; FRANCE; TIME; METAANALYSIS;
D O I
10.1007/s40272-016-0180-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. Methods We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R-0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). Results Model calibration yielded R-0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. Conclusions The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
引用
收藏
页码:303 / 318
页数:16
相关论文
共 50 条
  • [21] Seasonal vaccination with the inactivated influenza vaccine generates antibody profiles that are distinct from those generated by the live-attenuated influenza vaccine
    Shagal, Ayelet
    Monto, Arnold
    Hertz, Tomer
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [22] Influenza Vaccination with a Live Attenuated Vaccine The role of the pediatric nurse in immunization compliance
    Michael, Michele
    Helm, Elizabeth
    Van Graafeiland, Brigit
    Malinoski, Frank
    Bauman, Jay
    AMERICAN JOURNAL OF NURSING, 2009, 109 (10) : 44 - 48
  • [23] Improving influenza vaccination in chronically ill children using a tertiary-care based vaccination clinic: Is there a role for the live-attenuated influenza vaccine (LAIV)?
    Merckx, Joanna
    McCormack, Deirdre
    Quach, Caroline
    VACCINE, 2016, 34 (06) : 750 - 756
  • [24] Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans
    Etchart, Nathalie
    Hennino, Ana
    Friede, Martin
    Dahel, Karima
    Dupouy, Monique
    Goujon-Henry, Catherine
    Nicolas, Jean-Francois
    Kaiserlian, Dominique
    VACCINE, 2007, 25 (39-40) : 6891 - 6899
  • [25] Using "pop-up" clinics and live-attenuated influenza vaccine to reduce barriers to flu vaccination among college students
    Benzaken, Casey
    Mithal, Leena
    Tan, Tina
    Jhaveri, Ravi
    JOURNAL OF AMERICAN COLLEGE HEALTH, 2024,
  • [26] FluMist storage:: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (vol 45, pg 65, 2003)
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2004, 46 (1176): : 16 - 16
  • [27] Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine
    Des Roches, Anne
    Samaan, Kathryn
    Graham, Francois
    Lacombe-Barrios, Jonathan
    Paradis, Jean
    Paradis, Louis
    De Serres, Gaston
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2015, 3 (01): : 138 - 139
  • [28] Epidemiological Impact of the Pediatric Live Attenuated Influenza Vaccine (LAIV) Program on Group A Streptococcus (GAS) Infection in England
    Sinnathamby, Mary A.
    Warburton, Fiona
    Guy, Rebecca
    Andrews, Nick
    Lamagni, Theresa
    Watson, Conall
    Bernal, Jamie Lopez
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (06):
  • [29] Immunizing pediatric liver transplant recipients against varicella virus using live-attenuated vaccination
    Harmann, Katherine
    Sear, Katherine
    Nadimpalli, Sruti
    Chen, Sharon F.
    Gans, Hayley
    Bensen, Rachel
    PEDIATRIC TRANSPLANTATION, 2022, 26
  • [30] PUBLIC HEALTH AND ECONOMIC IMPACT OF VACCINATING CHILDREN WITH A QUADRIVALENT LIVE ATTENUATED INFLUENZA VACCINE IN FRANCE USING A DYNAMIC TRANSMISSION MODEL
    Gerlier, L.
    Weil-Olivier, C.
    Carrat, F.
    Lenne, X.
    Lamotte, M.
    Greneche, S.
    Eichner, M.
    VALUE IN HEALTH, 2014, 17 (07) : A674 - A674